Hirata Y, Ishii M, Matsuoka H, Sugimoto T, Iizuka M, Uchida Y, Serizawa T, Sato H, Kohmoto O, Mochizuki T
Am Heart J. 1987 Jun;113(6):1463-9. doi: 10.1016/0002-8703(87)90663-6.
Plasma concentrations of immunoreactive alpha-human atrial natriuretic polypeptide (i alpha-hANP) and cyclic guanosine monophosphate (cGMP) were measured in 70 patients with heart disease. Plasma concentrations of i alpha-hANP were directly related to the severity of heart disease (F = 29.61, p less than 0.001). Plasma concentrations of i alpha-hANP were well correlated with pulmonary capillary wedge pressure (PCWP; r = 0.64, p less than 0.001), mean pulmonary arterial pressure (PAP; r = 0.62, p less than 0.001), and mean right atrial pressure (RAP; r = 0.75, p less than 0.001). Plasma concentrations of cGMP were also directly related to the severity of heart disease (F = 13.61, p less than 0.001) and highly correlated with plasma concentrations of i alpha-hANP (r = 0.73, p less than 0.001). Plasma concentrations of cGMP were also closely correlated with PCWP (r = 0.69, p less than 0.001), mean PAP (r = 0.61, p less than 0.001), and mean RAP (r = 0.60, p less than 0.001). The i alpha-hANP concentrations of plasma samples obtained from the coronary sinus were approximately fourfold higher than those of samples obtained from the pulmonary artery, whereas cGMP concentrations were comparable in plasma samples obtained from either site. Elevation of cGMP concentrations following intravenous infusion of synthetic alpha-hANP was comparable in plasma samples obtained from the coronary sinus and the pulmonary artery. These findings suggest that elevated plasma concentrations of i alpha-hANP in cardiac patients result from an increase in the secretion of ANPs, which is probably accelerated by elevation of right or left atrial pressure, and that plasma concentrations of cGMP reflect circulating levels of alpha-hANP.
对70例心脏病患者测定了免疫反应性α-人心房利钠多肽（iα-hANP）和环磷酸鸟苷（cGMP）的血浆浓度。iα-hANP的血浆浓度与心脏病的严重程度直接相关（F = 29.61，p < 0.001）。iα-hANP的血浆浓度与肺毛细血管楔压（PCWP；r = 0.64，p < 0.001）、平均肺动脉压（PAP；r = 0.62，p < 0.001）和平均右心房压（RAP；r = 0.75，p < 0.001）密切相关。cGMP的血浆浓度也与心脏病的严重程度直接相关（F = 13.61，p < 0.001），并且与iα-hANP的血浆浓度高度相关（r = 0.73，p < 0.001）。cGMP的血浆浓度也与PCWP（r = 0.69，p < 0.001）、平均PAP（r = 0.61，p < 0.001）和平均RAP（r = 0.60，p < 0.001）密切相关。从冠状窦采集的血浆样本中iα-hANP的浓度大约是从肺动脉采集的样本的四倍，而从两个部位采集的血浆样本中cGMP的浓度相当。静脉注射合成α-hANP后，冠状窦和肺动脉采集的血浆样本中cGMP浓度的升高相当。这些发现表明，心脏病患者血浆中iα-hANP浓度升高是由于心房利钠肽分泌增加所致，这可能是由右心房或左心房压力升高加速的，并且cGMP的血浆浓度反映了α-hANP的循环水平。
